PM
MRVI icon

Parametrica Management’s Maravai LifeSciences MRVI Stock Holding History

Parametrica Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,835
Closed -$241K – 262
2022
Q1 		$241K Buy
+6,835
New +$229K 0.18% 159

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Parametrica Management's MRVI Position: Q2 2022 in Review

Parametrica Management sold out of Maravai LifeSciences (MRVI) in Q2 2022, closing a stake of 6,835 shares — an estimated $241K sold.

Parametrica Management first reported a position in MRVI in Q1 2022 and held it in 1 quarter. The position peaked at $241K in Q1 2022. 216 funds tracked by Wall St. Rank hold MRVI as of Q2 2022.

  • Parametrica Management reported no remaining Maravai LifeSciences position as of Q2 2022 after selling out during the quarter.
  • Parametrica Management sold 6,835 Maravai LifeSciences shares in Q2 2022, an estimated $241K.
  • Parametrica Management first reported a position in Maravai LifeSciences in Q1 2022 and held it in 1 quarter.
  • Parametrica Management's Maravai LifeSciences position peaked at $241K in Q1 2022.
  • 216 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.